Dr. Snyder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-359-8111Fax+1 626-218-5310
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1980
- New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
- Harvard Medical SchoolClass of 1977
Certifications & Licensure
- CA State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- 11 citationsAllogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.Amandeep Salhotra, Michelle Afkhami, Dongyun Yang, Sally Mokhtari, Milhan Telatar
Clinical Lymphoma, Myeloma & Leukemia. 2019-07-01 - 191 citationsEfficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Ahmed Aribi, Haris Ali, Karamjeet S. Sandhu
Haematologica. 2018-09-01 - 53 citationsInvasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.Ibrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, Bernard Tegtmeier, Matthew Mei
Blood Advances. 2019-12-10
Abstracts/Posters
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- 2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative LeadershipDecember 8th, 2020
- Imetelstat Promising Across Myeloproliferative NeoplasmsSeptember 4th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: